Sat.Dec 24, 2022 - Fri.Dec 30, 2022

article thumbnail

The DDW Podcast: 2022 in review 

Drug Discovery World

As 2022 draws to a close, DDW’s Multimedia Editor and podcast host Megan Thomas rounds up all the free episodes of the DDW podcast that were released. 2022 saw the introduction of the DDW Highlights podcast as well as the In Conversation With podcast, and saw the continued success of the free narrated episodes and the sponsored Sitting Down With series. .

DNA 130
article thumbnail

Medical terms A to Z: Common and confusing terms used in the doctor’s office

Antidote

Generally, a doctor’s visit is intended to provide clarity and insight into a patient’s concerns — but many people are all too familiar with the feeling of walking out of a clinic more confused than when they arrived. In fact, many Americans find themselves searching for health literacy tips after becoming confused by a doctor’s instructions or the directions on a prescription label.

98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

USA Clinical Trial Market Size and Opportunities

ProRelix Research

Clinical trials form the crux of all regulatory decisions regarding any new health intervention such as drugs and medical devices and thus require to be performed with the utmost care […]. The post USA Clinical Trial Market Size and Opportunities appeared first on ProRelix Research.

article thumbnail

New patent expiration for Novo Nordisk drug VICTOZA

Drug Patent Watch

Annual Drug Patent Expirations for VICTOZA Victoza is a drug marketed by Novo Nordisk Inc and is included in one NDA. It is available from two suppliers. There are seven…. The post New patent expiration for Novo Nordisk drug VICTOZA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Top Perspectives Articles of 2022

Cytel

Perspectives on Enquiry and Evidence explores a wide variety of topics within clinical trial design and data science in the form of expert articles, interviews, ebooks, and more. Here are some of our most read posts of 2022.

article thumbnail

EOY wrap-up: What’s ahead in clinical trial patient recruitment?

Antidote

Though clinical trials as we know them have only existed since the 1980s , the past 40 years have been ripe with innovations in the process. From an increased focus on the patient experience to the rise of clinical trial matching software, the world of medical research continues to grow and evolve.

More Trending

article thumbnail

New patent for Epi Hlth drug RHOFADE

Drug Patent Watch

Annual Drug Patent Expirations for RHOFADE Rhofade is a drug marketed by Epi Hlth and is included in one NDA. It is available from one supplier. There are seven patents…. The post New patent for Epi Hlth drug RHOFADE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Top Bayesian Topics of 2022

Cytel

Bayesian methods have been playing a key role in transforming clinical research, providing a variety of new opportunities for efficient and flexible clinical trials. Bayesian topics are frequently explored in Perspectives on Enquiry and Evidence. Here are some of our most-read articles on Bayesian methods in 2022.

article thumbnail

Nirsevimab

New Drug Approvals

(Heavy chain) QVQLVQSGAE VKKPGSSVMV SCQASGGLLE DYIINWVRQA PGQGPEWMGG IIPVLGTVHY GPKFQGRVTI TADESTDTAY MELSSLRSED TAMYYCATET ALVVSETYLP HYFDNWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKRVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL YITREPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LH

Virus 52
article thumbnail

So Long to All that Junk

Drug & Device Law

As we prepare to greet 2023, we find ourselves assuming the Janus-ian posture of simultaneously looking backward and forward. Forward is more fun, as we scan a schedule full of motions, MDL decision-trees, and trials in, er, challenging jurisdictions. But it really is folly to plan the future without learning from the past. It is hard to beat Bexis’s lists of the best and worst DDL cases, the latter of which graced us last week , and the former of which will adorn this blog tomorrow, for inve

Science 59
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

New tentative approval for Teva Pharms drug eltrombopag

Drug Patent Watch

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New tentative approval for Amneal Pharms drug saxagliptin

Drug Patent Watch

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Azurity drug ZONISADE

Drug Patent Watch

Annual Drug Patent Expirations for ZONISADE Zonisade is a drug marketed by Azurity and is included in one NDA. It is available from one supplier. There is one patent protecting…. The post New patent for Azurity drug ZONISADE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for HANDA drug TASCENSO ODT

Drug Patent Watch

Annual Drug Patent Expirations for TASCENSO+ODT Tascenso Odt is a drug marketed by Handa and is included in one NDA. There are three patents protecting this drug. This drug has…. The post New patent for HANDA drug TASCENSO ODT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

New tentative approval for Teva Pharms drug eltrombopag

Drug Patent Watch

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New tentative approval for Amneal Pharms drug saxagliptin

Drug Patent Watch

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Drug Patent Expirations for the Week of December 25, 2022

Drug Patent Watch

VICTOZA (liraglutide recombinant) Novo nordisk inc Patent: 8,846,618 Expiration: Dec 27, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact…. The post Drug Patent Expirations for the Week of December 25, 2022 appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent expiration for NOVO drug SAXENDA

Drug Patent Watch

Annual Drug Patent Expirations for SAXENDA Saxenda is a drug marketed by Novo and is included in one NDA. It is available from two suppliers. There are twenty-five patents protecting…. The post New patent expiration for NOVO drug SAXENDA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent expiration for Baudax drug ANJESO

Drug Patent Watch

Annual Drug Patent Expirations for ANJESO Anjeso is a drug marketed by Baudax and is included in one NDA. There are eight patents protecting this drug. Drug patent litigation for…. The post New patent expiration for Baudax drug ANJESO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New tentative approval for Amneal Pharms drug saxagliptin

Drug Patent Watch

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

New tentative approval for Teva Pharms drug eltrombopag

Drug Patent Watch

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

New tentative approval for Amneal Pharms drug saxagliptin

Drug Patent Watch

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

New tentative approval for Teva Pharms drug eltrombopag

Drug Patent Watch

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

New tentative approval for Teva Pharms drug eltrombopag

Drug Patent Watch

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

New tentative approval for Amneal Pharms drug saxagliptin

Drug Patent Watch

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

New tentative approval for Amneal Pharms drug saxagliptin

Drug Patent Watch

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

New tentative approval for Teva Pharms drug eltrombopag

Drug Patent Watch

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

New tentative approval for Amneal Pharms drug saxagliptin

Drug Patent Watch

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

New tentative approval for Teva Pharms drug eltrombopag

Drug Patent Watch

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

Which pharmaceutical companies have the most drug patents in Slovakia?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Slovakia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Slovakia? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Which pharmaceutical companies have the most gel dosed drugs?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most gel dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most gel dosed drugs…. The post Which pharmaceutical companies have the most gel dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Which pharmaceutical drugs have the most drug patents in Croatia?

Drug Patent Watch

This chart shows the drugs with the most patents in Croatia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Croatia? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Which pharmaceutical companies have the most drug patents in Denmark?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Denmark. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Denmark? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Which pharmaceutical companies have the most emulsion dosed drugs?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most emulsion dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most emulsion dosed drugs…. The post Which pharmaceutical companies have the most emulsion dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.